Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GOVX 
GeoVax Labs Inc (GOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: GOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -81.27% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.47M USD | Price to earnings Ratio - | 1Y Target Price 14.6 |
Price to earnings Ratio - | 1Y Target Price 14.6 | ||
Volume (30-day avg) 639156 | Beta 3.07 | 52 Weeks Range 1.09 - 11.18 | Updated Date 03/30/2025 |
52 Weeks Range 1.09 - 11.18 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -209.88% |
Management Effectiveness
Return on Assets (TTM) -112.1% | Return on Equity (TTM) -276.02% |
Valuation
Trailing PE - | Forward PE 10.63 | Enterprise Value 9054616 | Price to Sales(TTM) 3.39 |
Enterprise Value 9054616 | Price to Sales(TTM) 3.39 | ||
Enterprise Value to Revenue 2.93 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 9436070 | Shares Floating 8895948 |
Shares Outstanding 9436070 | Shares Floating 8895948 | ||
Percent Insiders 0.32 | Percent Institutions 5.67 |
Analyst Ratings
Rating 4.6 | Target Price 14.6 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GeoVax Labs Inc
Company Overview
History and Background
GeoVax Labs, Inc. was founded in 2001. It is a biotechnology company developing immunotherapies and vaccines to prevent and treat infectious diseases and cancer. The company has focused on developing its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform.
Core Business Areas
- Vaccines and Immunotherapies: Development and commercialization of vaccines and immunotherapies against infectious diseases, cancer and emerging threats using its MVA-VLP platform.
Leadership and Structure
David Dodd is the Chairman of the Board and President & CEO. The company has a standard corporate structure with departments for research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- GEO-CM04S1 (COVID-19 Vaccine): A vaccine candidate against COVID-19 utilizing the MVA-VLP platform. Clinical trials are ongoing. Market share is currently 0 as the product is not approved, with primary competitors being Pfizer (PFE), Moderna (MRNA), and Novavax (NVAX).
- Gedeptin (Hepatocellular Carcinoma Immunotherapy): An immunotherapy for hepatocellular carcinoma being developed in collaboration with partners. Currently in development. Competitors are Bristol Myers Squibb (BMY) and Roche (RHHBY).
- GEO-HIV (HIV Vaccine): A vaccine candidate against HIV also utilizing the MVA-VLP platform. Being developed. No revenue yet as the product is in clinical trials. Competitors are Gilead Sciences (GILD) and Viatris (VTRS).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with constant research and development of new therapies and vaccines. Stringent regulatory requirements and lengthy clinical trial processes are the norms.
Positioning
GeoVax is a clinical-stage biotechnology company focused on vaccine and immunotherapy development. Its competitive advantage lies in its proprietary MVA-VLP platform, which is designed to elicit both antibody and T-cell immune responses.
Total Addressable Market (TAM)
The global vaccine market is estimated to be worth hundreds of billions. GeoVax is positioned to capture a portion of this TAM through the development of novel vaccines, but faces stiff competition from larger companies.
Upturn SWOT Analysis
Strengths
- Proprietary MVA-VLP vaccine platform
- Strong preclinical and clinical data for lead candidates
- Experienced management team
- Partnerships for development and commercialization
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No currently marketed products
- High cash burn rate
Opportunities
- Expanding pipeline through internal development and partnerships
- Securing regulatory approvals for lead candidates
- Addressing unmet needs in infectious diseases and cancer
- Potential for government funding and grants
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- NVAX
- GILD
- BMY
Competitive Landscape
GeoVax is a smaller player competing with larger, more established pharmaceutical companies. Its MVA-VLP platform offers a potential competitive advantage, but it faces significant challenges in terms of resources and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: GeoVax's growth has been driven by advancements in its pipeline and partnerships. However, lack of product approval hinders substantial revenue growth.
Future Projections: Future growth depends on clinical trial results and regulatory approvals. Analyst estimates are not available in structured format.
Recent Initiatives: Recent initiatives include advancing clinical trials for GEO-CM04S1 and Gedeptin, and forming new partnerships to expand its pipeline.
Summary
GeoVax is a clinical-stage biotech company focused on vaccine and immunotherapy development. Its strength lies in its MVA-VLP platform, yet it faces challenges due to limited financial resources and the need for clinical trial success. Future growth hinges on obtaining regulatory approvals and securing strategic partnerships. It needs to be wary of stronger competition from larger pharmaceutical corporations.
Similar Companies
- VBI
- OCGN
- INO
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeoVax Labs Inc
Exchange NASDAQ | Headquaters Smyrna, GA, United States | ||
IPO Launch date 1999-04-09 | Chairman, President & CEO Mr. David Alan Dodd | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.geovax.com |
Full time employees 17 | Website https://www.geovax.com | ||
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.